The biggest pharmacy benefit managers are profiting by systematically underpaying independent drugstores, creating “pharmacy ...

Judge Karen Marston held that, despite plaintiffs' arguments to the contrary, marketing discovery is not relevant to the ...

Danish drugmaker Novo Nordisk has made billions of dollars from its GLP-1s, including pills and injectable drugs like Ozempic ...

Leerink Partnrs analyst D. Risinger now expects that the company will earn $1.24 per share for the quarter, […] ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and ...

In a new study examining people with opioid or alcohol use disorder, prescriptions for Ozempic, Wegovy, Mounjaro, and ...

Of those, there were roughly 8,100 people and 5,600 people, respectively, who had a prescription for a GIP/GLP-1 receptor ...

The stock of Eli Lilly and Company LLY has declined 1.7% already this week, losing almost $14 billion of its market value.

"Johnson & Johnson and Mitsubishi Tanabe Pharma’s Stelara (ustekinumab) and Eli Lilly and Sumitomo Dainippon Pharma’s Trulicity (dulaglutide) are ranked ninth and tenth,” Sabaratnam says.

Equities researchers at Zacks Research issued their Q3 2024 earnings per share (EPS) estimates for shares of Eli Lilly and ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best rising ...